
|Podcasts|October 1, 2020
Episode 66: New Approach to Antithrombotics
Author(s)Elaine Quilici
Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.
Advertisement
Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Who Pays for Tariff Driven Input Cost Increases?
2
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
3
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
4
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
5
